Navigation Links
Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
Date:10/2/2008

- Two Milestones Reached in Zonisamide Patent Portfolio -

SAN DIEGO, Oct. 2 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced the initiation of its first clinical trial with OREX-003, a proprietary sustained release formulation of zonisamide plus olanzapine. The Phase 2a clinical trial, OZ-101, is designed to examine the effectiveness of OREX-003 in mitigating drug-associated weight gain and/or other metabolic consequences commonly experienced by patients taking atypical antipsychotic medications, as well as the potential enhancement of antipsychotic activity.

In additional Company news, the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,425,571 providing broad coverage of the use of zonisamide either alone or in combination with other drugs for the treatment of obesity through 2023. The USPTO has also issued U.S. Patent No. 7,429,580 which broadly covers zonisamide in combination with various marketed atypical antipsychotics including olanzapine, clozapine, risperidone, quetiapine, aripiprazole and ziprasidone through 2025. We believe that these patents complement each other and provide a strong patent portfolio for OREX-003. Orexigen has licensed both patents on an exclusive basis from Duke University.

"The initiation of the OZ-101 clinical trial and progress in securing comprehensive intellectual property coverage for zonisamide are important milestones for Orexigen as we grow our product candidate pipeline beyond our initial obesity programs by extending into other central nervous system disorders," said Gary Tollefson, M.D.,
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Ontario (PRWEB) May 21, 2015 ... into an exclusive North American distribution agreement with ... testing system. , With more than 160 years ... products and services for laboratory and production facilities, ... operational excellence and differentiated services to enable science. ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) has announced ... Insights" report to their offering. Technical ... the Health and Wellness sector and has identified top ... in the year 2015. The research service provides an ... wellness technologies that are anticipated to have the highest ...
(Date:5/20/2015)...  Select Medical Corporation ("Select") (NYSE: SEM ... early termination of the waiting period under the ... amended, applicable to the acquisition of Concentra Inc. ... that Select has created with Welsh, Carson, Anderson & ... MJ Acquisition Corporation has signed a definitive purchase ...
(Date:5/20/2015)... Westport, CT (PRWEB) May 20, 2015 ... the 10th anniversary of its acquisition of Tiger-Sul. ... from Enersul (Calgary Alberta, Canada) in May 2005, H.J. ... line to build it into a comprehensive portfolio of ... the strength of H.J. Baker and the innovation of ...
Breaking Biology Technology:Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Top Technologies in the Health and Wellness Industry 2015 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 3
... 19 Encorium Group, Inc. (Nasdaq: ENCO ), ... design, development, and management capabilities for clinical trials and ... companies, today announced that it has completed a private ... a private investor for an aggregate purchase price of ...
... will report findings today (Oct. 19) that demonstrate ... dramatically reduce cartilage degeneration. , The discovery by scientists ... a Massachusetts-based startup company, could result in a new ... , The study, by Gregory D. Jay, MD, PhD, ...
... BEIJING, Oct. 19 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies,Inc. ... medical device,company that develops, manufactures and markets advanced in-vitro ... for its SPR-,based analysis system (the "SPR System") from ... , The SPR System utilizes ...
Cached Biology Technology:Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY 2Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY 3Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY 4Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY 5Lubris, Biomodels Report on Potential New Therapy for Osteoarthritis 2China Medical Technologies Announces the SFDA Approval for its SPR System 2China Medical Technologies Announces the SFDA Approval for its SPR System 3
(Date:5/19/2015)... 2015  Technology is rapidly advancing, outpacing enterprises, ability ... cloud. Passwords and their management are soon to be ... specifications such as those developed by the FIDO Alliance™. ... presents for BYOD, COPE, IoT, and mobile payments, the ... In response to the call for ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
(Date:5/7/2015)... GOTHENBURG, Sweden , May 7, 2015 /PRNewswire/ ... new touch fingerprint sensors, FPC1022 and FPC1035, FPC,s ... FPC1022 and FPC1035 are mainly considered for integration ... decreased size gives smartphone OEMs increased possibilities to ... portfolio. The decreased size also improves possibilities for ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... been thought to be important only to translate a gene's ... evidence shows that tiny bits of RNA not used to ... in the development of cancers. , "Scientists have known for ... as microRNAs, is only supposed to happen at certain times ...
... producing embryonic-like cells from umbilical cord blood may substantially ... injuries and disabilities. The discovery made during a project ... Branch and the Synthecon Corporation in the United States ... reliable source of human stem cells for the first ...
... who take soy or herbal supplements, such as black ... care, says a Cornell University expert affiliated with the ... at Cornell, the land-grant institution of New York state. ... herbal medicines can increase or decrease breast cancer risk, ...
Cached Biology News:Once given 'no respect,' cells' tiny RNAS take driver's seat 2Once given 'no respect,' cells' tiny RNAS take driver's seat 3Researchers propose measures to curb lion attacks in Tanzania 2Women cautioned against using herbal supplements 2Women cautioned against using herbal supplements 3